ACM
SNDX icon

Atika Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Atika Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-40,000
Closed -$864K – 112
2023
Q4 		$864K Buy
+40,000
New +$615K 0.12% 72

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Atika Capital Management's SNDX Position: Q1 2024 in Review

Atika Capital Management sold out of Syndax Pharmaceuticals (SNDX) in Q1 2024, closing a stake of 40,000 shares — an estimated $864K sold.

Atika Capital Management first reported a position in SNDX in Q4 2023 and held it in 1 quarter. The position peaked at $864K in Q4 2023. 189 funds tracked by Wall St. Rank hold SNDX as of Q1 2024.

  • Atika Capital Management reported no remaining Syndax Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Atika Capital Management sold 40,000 Syndax Pharmaceuticals shares in Q1 2024, an estimated $864K.
  • Atika Capital Management first reported a position in Syndax Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Atika Capital Management's Syndax Pharmaceuticals position peaked at $864K in Q4 2023.
  • 189 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2024.

Based on Atika Capital Management's 13F filing for Q1 2024, filed 14 May 2024.